专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120157335A1 Flap Endonuclease-1 As A Marker For Cancer 审中-公开
标题翻译：瓣内切核酸酶-1作为癌症的标志物
公开(公告)号：US20120157335A1
公开(公告)日：2012-06-21
申请号：US13351801
申请日：2012-01-17
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
IPC分类号： C40B30/04 , G01N33/573 , C40B40/10 , G01N33/574 , C07K16/40
CPC分类号： G01N33/573 , G01N33/54306 , G01N33/57411 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/5743 , G01N33/57434 , G01N33/57438 , G01N33/57442 , G01N33/57449 , G01N33/57488 , G01N2333/922 , G01N2800/52 , G01N2800/7028 , G16H50/30 , Y02A90/26
摘要： Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
摘要翻译：提供了帮助评估癌症的方法，包括使用Flap核酸内切酶-1蛋白（= FEN1）作为不同癌症类型的通用标记。特别地，公开了从样品中得到的来自个体的液体样品中评估癌症的方法，其包括测量样品中的FEN1。 FEN1的测量可用于癌症的早期检测或用于手术切除肿瘤的患者的监测。

2. 发明授权

US09518990B2 Secernin-1 as a marker for cancer 有权
标题翻译： Secernin-1作为癌症的标志物
公开(公告)号：US09518990B2
公开(公告)日：2016-12-13
申请号：US13272399
申请日：2011-10-13
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
IPC分类号： G01N1/00 , G01N33/00 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/574
CPC分类号： G01N33/57484
摘要： Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。它涉及使用Secernin-1蛋白（SCRN1）作为不同癌症类型的通用标记物。更具体地公开了通过测量样品中的SCRN1来从源自个体的液体样品中评估癌症的方法。 SCRN1的测定可以例如用于癌症的早期检测或者进行手术的患者的监视。

3. 发明申请

US20110212465A1 ARMET AS A MARKER FOR CANCER 有权
标题翻译： ARMET作为癌症的标记
公开(公告)号：US20110212465A1
公开(公告)日：2011-09-01
申请号：US13103123
申请日：2011-05-09
申请人： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
发明人： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
IPC分类号： G01N33/68 , G01N33/566
CPC分类号： G01N33/57488 , G01N33/57423 , G01N33/57484 , G01N2333/475 , G01N2800/52
摘要： Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

4. 发明授权

US08951738B2 CYBP as a marker for lung cancer 有权
标题翻译： CYBP作为肺癌的标志物
公开(公告)号：US08951738B2
公开(公告)日：2015-02-10
申请号：US13270482
申请日：2011-10-11
申请人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
发明人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/57423 , G01N2333/4727
摘要： The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
摘要翻译：本发明涉及肺癌的评估。它公开了蛋白CYBP在肺癌评估中的应用。它还涉及一种通过在所述样品中测量CYBP在体外使用来自个体的液体样品来评估肺癌的方法。 CYBP的测量可以例如用于肺癌患者的早期检测或随访。

5. 发明授权

US08741587B2 ARMET as a marker for cancer 有权
标题翻译： ARMET作为癌症的标志物
公开(公告)号：US08741587B2
公开(公告)日：2014-06-03
申请号：US13103123
申请日：2011-05-09
申请人： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
发明人： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , G01N33/57423 , G01N33/57484 , G01N2333/475 , G01N2800/52
摘要： Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

6. 发明申请

US20120196303A1 CYBP AS A MARKER FOR LUNG CANCER 有权
标题翻译： CYBP作为肺癌标志物
公开(公告)号：US20120196303A1
公开(公告)日：2012-08-02
申请号：US13270482
申请日：2011-10-11
申请人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
发明人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
IPC分类号： G01N33/53
CPC分类号： G01N33/57423 , G01N2333/4727
摘要： The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
摘要翻译：本发明涉及肺癌的评估。它公开了蛋白CYBP在肺癌评估中的应用。它还涉及一种通过在所述样品中测量CYBP在体外使用来自个体的液体样品来评估肺癌的方法。 CYBP的测量可以例如用于肺癌患者的早期检测或随访。

7. 发明申请

US20130344505A1 APEX1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 审中-公开
标题翻译： APEX1作为慢性阻塞性肺疾病（COPD）的标记
公开(公告)号：US20130344505A1
公开(公告)日：2013-12-26
申请号：US14022297
申请日：2013-09-10
申请人： Marie-Luise Hagmann , Johann Karl , Julia Riedlinger
发明人： Marie-Luise Hagmann , Johann Karl , Julia Riedlinger
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/914 , G01N2800/122 , G01N2800/60
摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein APEX1 in said sample in vitro.
摘要翻译：一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。本公开还涉及通过在体外测量所述样品中的蛋白质APEX1来评估来自个体的样品的COPD的方法。

8. 发明申请

US20130344516A1 ARMET AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 审中-公开
公开(公告)号：US20130344516A1
公开(公告)日：2013-12-26
申请号：US14022276
申请日：2013-09-10
申请人： Johann Karl , Julia Riedlinger , Markus Roessler
发明人： Johann Karl , Julia Riedlinger , Markus Roessler
IPC分类号： G01N33/68
CPC分类号： G01N33/6884 , G01N33/6893 , G01N2333/47 , G01N2800/122 , G01N2800/60
摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro.

9. 发明申请

US20140004544A1 FEN1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 审中-公开
标题翻译： FEN1作为慢性阻塞性肺疾病（COPD）的标记
公开(公告)号：US20140004544A1
公开(公告)日：2014-01-02
申请号：US14022289
申请日：2013-09-10
申请人： Johann Karl , Julia Riedlinger , Norbert Wild
发明人： Johann Karl , Julia Riedlinger , Norbert Wild
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6884 , G01N2333/914 , G01N2333/916 , G01N2800/122 , G01N2800/60
摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.
摘要翻译：一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。本公开还涉及通过在体外测量所述样品中的蛋白质FEN1来评估来自个体的样品的COPD的方法。

10. 发明申请

US20130344506A1 SEPRASE AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 审中-公开
标题翻译： SEPRASE作为慢性阻塞性肺疾病（COPD）的标记
公开(公告)号：US20130344506A1
公开(公告)日：2013-12-26
申请号：US14022309
申请日：2013-09-10
申请人： Johann Karl , Julia Riedlinger , Wolfgang Rollinger
发明人： Johann Karl , Julia Riedlinger , Wolfgang Rollinger
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6884 , G01N2333/96433 , G01N2800/122 , G01N2800/60
摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein Seprase in said sample in vitro.
摘要翻译：一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。本公开还涉及通过在体外测量所述样品中的蛋白质Seprase，从源自个体的样品中评估COPD的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式